Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

(2013) Clifford R Jack et al.   LANCET NEUROLOGY

The Application of Cerebrospinal Fluid Biomarkers in Early Diagnosis of Alzheimer Disease

(2013) Kaj Blennow et al.   MEDICAL CLINICS OF NORTH AMERICA

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

(2013) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Isolated Amyloid-β(1–42) Protofibrils, But Not Isolated Fibrils, Are Robust Stimulators of Microglia

(2012) Geeta S. Paranjape et al.   ACS Chemical Neuroscience

Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease

(2012) Martin Farlow et al.   Alzheimers & Dementia

Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease

(2012) Henrik Zetterberg   ARCHIVES OF NEUROLOGY

A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline

(2012) Thorlakur Jonsson et al.   NATURE

Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers

(2012) M. Scholl et al.   NEUROLOGY

Large Aggregates Are the Major Soluble Aβ Species in AD Brain Fractionated with Density Gradient Ultracentrifugation

(2012) Dag Sehlin et al.   PLoS One

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease

(2011) S. Salloway et al.   NEUROLOGY

Pyroglutamate-Aβ: Role in the natural history of Alzheimer's disease

(2010) Adam P. Gunn et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Amyloid  -Protein Dimers Rapidly Form Stable Synaptotoxic Protofibrils

(2010) B. O'Nuallain et al.   JOURNAL OF NEUROSCIENCE

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

(2010) Juha O Rinne et al.   LANCET NEUROLOGY

Decreased Clearance of CNS  -Amyloid in Alzheimer's Disease

(2010) K. G. Mawuenyega et al.   SCIENCE

Rate of progression of mild cognitive impairment to dementia - meta-analysis of 41 robust inception cohort studies

(2009) A. J. Mitchell et al.   ACTA PSYCHIATRICA SCANDINAVICA

Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders

(2009) Bruno Vellas et al.   Current Alzheimer Research

Amyloid-β protofibril levels correlate with spatial learning in Arctic Alzheimer’s disease transgenic mice

(2009) Anna Lord et al.   FEBS Journal

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

(2009) Clifford R Jack et al.   LANCET NEUROLOGY

An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease

(2009) Anna Lord et al.   NEUROBIOLOGY OF DISEASE

Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study

(2009) A. Okello et al.   NEUROLOGY

Molecular genetics of Alzheimer's disease: An update

(2008) Nathalie Brouwers et al.   ANNALS OF MEDICINE